Sale of Priority Review Vouchers (Details) - USD ($) $ in Thousands			12 Months Ended
	Jan. 05, 2023	Dec. 29, 2022	Dec. 31, 2023	Dec. 31, 2022
Asset Acquisition [Line Items]
Proceeds from sale of priority review voucher			$ 92,930	$ 102,000
Argenx BV | PRV
Asset Acquisition [Line Items]
Proceeds from sale of priority review voucher		$ 102,000
Bristol-Myers Squibb
Asset Acquisition [Line Items]
Transaction costs	$ 2,100
Bristol-Myers Squibb | PRV
Asset Acquisition [Line Items]
Proceeds from sale of priority review voucher	$ 95,000